GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
J

Jiangsu Nhwa Pharmaceutical Co 002262.SZ · CNY

Health Care · Shenzhen · 🇨🇳 China

Compare

22.56

-1.36%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥5.91bn

FY2016FY2025

Net income

CN¥1.06bn

FY2016FY2025

Free cash flow

CN¥641.0m

FY2016FY2025

Shareholders' equity

CN¥8.06bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥5.91bnCN¥5.70bnCN¥5.04bnCN¥4.30bnCN¥3.94bnCN¥3.36bnCN¥4.15bnCN¥3.86bnCN¥3.39bnCN¥3.02bn
Gross profitCN¥4.26bnCN¥4.15bnCN¥3.64bnCN¥3.26bnCN¥3.00bnCN¥2.52bnCN¥2.59bnCN¥2.14bnCN¥1.61bnCN¥1.38bn
Research and developmentCN¥685.5mCN¥611.5mCN¥549.3mCN¥454.3mCN¥351.7mCN¥245.9mCN¥189.0mCN¥172.0mCN¥111.4mCN¥73.2m
Operating incomeCN¥1.16bnCN¥1.34bnCN¥1.18bnCN¥1.00bnCN¥925.9mCN¥856.1mCN¥770.8mCN¥609.9mCN¥445.9mCN¥354.0m
Net incomeCN¥1.06bnCN¥1.14bnCN¥1.04bnCN¥900.7mCN¥797.8mCN¥728.8mCN¥663.3mCN¥524.8mCN¥394.6mCN¥309.7m
Diluted earnings per share1.041.131.030.870.800.700.670.520.390.31

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥9.22bnCN¥8.44bnCN¥7.33bnCN¥6.48bnCN¥5.70bnCN¥4.81bnCN¥4.20bnCN¥4.03bnCN¥3.30bnCN¥2.97bn
Cash and short-term investments—CN¥3.79bnCN¥3.49bnCN¥2.98bnCN¥2.67bnCN¥2.24bnCN¥1.89bnCN¥1.11bnCN¥1.13bnCN¥879.9m
Total liabilitiesCN¥1.20bnCN¥1.17bnCN¥918.1mCN¥897.4mCN¥793.5mCN¥706.7mCN¥596.7mCN¥1.07bnCN¥840.2mCN¥851.0m
DebtCN¥230,000CN¥49.1mCN¥90.8mCN¥72.1mCN¥85.9mCN¥83.8mCN¥38.2mCN¥317.6mCN¥232.4mCN¥263.2m
Shareholders' equityCN¥8.06bnCN¥7.30bnCN¥6.43bnCN¥5.62bnCN¥4.92bnCN¥4.12bnCN¥3.62bnCN¥2.96bnCN¥2.45bnCN¥2.10bn
Shares outstanding1,014m1,012m1,008m1,041m993m1,041m994m1,009m1,009m1,009m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥1.08bnCN¥916.1mCN¥1.01bnCN¥861.0mCN¥701.1mCN¥1.25bnCN¥306.0mCN¥404.5mCN¥452.3mCN¥277.1m
Capital spending−CN¥437.4m−CN¥450.1m−CN¥374.0m−CN¥327.8m−CN¥206.1m−CN¥268.6m−CN¥160.3m−CN¥170.7m−CN¥166.0m−CN¥102.2m
Free cash flowCN¥641.0mCN¥466.1mCN¥634.3mCN¥533.3mCN¥495.0mCN¥979.7mCN¥145.7mCN¥233.8mCN¥286.3mCN¥174.9m
Dividends paid−CN¥366.2m−CN¥323.8m−CN¥201.5m−CN¥201.5m−CN¥100.8m−CN¥101.9m−CN¥77.1m−CN¥64.0m−CN¥46.4m−CN¥40.7m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥1.61bnCN¥1.61bnCN¥1.44bnCN¥1.46bnCN¥1.50bnCN¥1.51bnCN¥1.55bnCN¥1.38bn
Gross profitCN¥1.23bnCN¥1.14bnCN¥864.6mCN¥1.13bnCN¥1.13bnCN¥1.13bnCN¥1.09bnCN¥1.06bn
Operating incomeCN¥492.1mCN¥359.0m−CN¥41.8mCN¥426.5mCN¥454.3mCN¥338.6mCN¥165.2mCN¥438.8m
Net incomeCN¥423.3mCN¥317.4m−CN¥48.7mCN¥405.6mCN¥399.8mCN¥300.7mCN¥123.5mCN¥391.2m
Diluted earnings per share0.420.31-0.050.400.390.300.120.39
Cash from operations———CN¥425.0mCN¥175.0mCN¥319.0mCN¥4.0mCN¥289.0m
Capital spending−CN¥76.0m−CN¥80.0m−CN¥204.0m−CN¥80.0m−CN¥78.0m−CN¥72.0m−CN¥170.0m−CN¥69.0m
Free cash flow———CN¥345.0mCN¥97.0mCN¥247.0m−CN¥166.0mCN¥220.0m
Total assetsCN¥9.54bnCN¥9.64bnCN¥9.22bnCN¥9.08bnCN¥8.79bnCN¥8.87bnCN¥8.44bnCN¥8.13bn
Cash and short-term investments———CN¥3.97bnCN¥3.69bnCN¥3.99bnCN¥3.79bnCN¥3.85bn
DebtCN¥230,000CN¥230,000CN¥230,000CN¥259.7mCN¥40.2mCN¥10.2mCN¥15.2mCN¥65.2m
Shareholders' equityCN¥8.39bnCN¥8.37bnCN¥8.06bnCN¥8.10bnCN¥7.67bnCN¥7.62bnCN¥7.30bnCN¥7.13bn

Financial ratios

Data as of 24 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin72.1%72.9%72.2%75.9%76.3%74.9%
Operating margin19.6%23.5%23.5%23.3%23.5%25.5%
Net margin17.9%20.1%20.6%21.0%20.3%21.7%
Return on equity13.1%15.7%16.1%16.0%16.2%17.7%
Return on assets11.5%13.5%14.1%13.9%14.0%15.1%
Free cash flow yield7.1%6.4%6.5%5.4%4.3%6.9%
Revenue growth3.7%13.0%17.3%9.2%17.1%-19.0%
Earnings growth-7.5%10.3%15.1%12.9%9.5%9.9%
Current ratio5.92x5.68x6.46x5.86x5.93x5.60x
Debt to equity0.00x0.00x0.01x0.01x0.01x0.01x
Equity ratio87.4%86.5%87.8%86.7%86.4%85.7%
Interest coverage475.86x252.22x238.19x177.56x151.74x348.09x
R&D as a share of sales11.6%10.7%10.9%10.6%8.9%7.3%
Buybacks as a share of market value-0.2%-0.4%3.2%-4.8%4.6%-4.7%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue11.2%12.0%7.9%
Operating income5.0%6.3%14.7%
Net income5.5%7.7%15.1%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin72.5%73.1%73.8%65.4%
Operating margin21.5%22.4%22.9%19.7%
Net margin19.0%19.8%20.1%17.2%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings23.121.626.428.419.522.817.417.336.542.5
Price to sales4.14.35.45.94.05.02.82.44.24.4

Dividends and splits

Per share, in the currency the company pays

Paid for 17 years. Last went ex-dividend on 26 May 2026.

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Paid in the year0.400.360.320.200.200.100.100.06
  • 8-for-5 split · 12 May 2017
  • 13-for-10 split · 8 Jun 2016
  • 6-for-5 split · 8 Apr 2015
  • 6-for-5 split · 28 May 2014
  • 13-for-10 split · 1 Jun 2010
  • 3-for-2 split · 10 Jun 2009

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.